These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 1261157)
1. N-Acetylprocainamide levels in patients with end-stage renal failure. Gibson TP; Matusik EJ; Briggs WA Clin Pharmacol Ther; 1976 Feb; 19(2):206-12. PubMed ID: 1261157 [TBL] [Abstract][Full Text] [Related]
2. Kinetics of procainamide and N-acetylprocainamide in renal failure. Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192 [TBL] [Abstract][Full Text] [Related]
3. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089 [TBL] [Abstract][Full Text] [Related]
5. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. Dutcher JS; Strong JM; Lucas SV; Lee WK; Atkinson AJ Clin Pharmacol Ther; 1977 Oct; 22(4):447-57. PubMed ID: 902457 [TBL] [Abstract][Full Text] [Related]
6. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496 [TBL] [Abstract][Full Text] [Related]
7. Elimination of procainamide in end stage renal failure. Gibson TP; Lowenthal DT; Nelson HA; Briggs WA Clin Pharmacol Ther; 1975 Mar; 17(3):321-9. PubMed ID: 1120398 [TBL] [Abstract][Full Text] [Related]
8. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560 [TBL] [Abstract][Full Text] [Related]
10. Polymorphic acetylation procainamide in man. Reidenberg MM; Drayer DE; Levy M; Warner H Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647 [TBL] [Abstract][Full Text] [Related]
11. The relationship between the metabolism of procainamide and sulfamethazine. Giardina E-GV ; Stein RM; Bigger JT Circulation; 1977 Feb; 55(2):388-94. PubMed ID: 832354 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype]. Gawrońska-Szklarz B; Górnik W; Kutrzeba J; Wójcicki J; Zakrzewski J Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):921-3. PubMed ID: 1284448 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250 [TBL] [Abstract][Full Text] [Related]
14. The quantitative disposition of procainamide and N-acetylprocainamide in the rat. Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132 [TBL] [Abstract][Full Text] [Related]
15. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468 [TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982 [TBL] [Abstract][Full Text] [Related]
17. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. Atkinson AJ; Krumlovsky FA; Huang CM; del Greco F Clin Pharmacol Ther; 1976 Nov; 20(5):585-92. PubMed ID: 975731 [TBL] [Abstract][Full Text] [Related]
18. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition. Jung D; Nanavaty M; Prasad P Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212 [TBL] [Abstract][Full Text] [Related]
19. Monitoring of procainamide and N-acetylprocainamide concentration in saliva after oral administration of procainamide. Koike Y; Mineshita S; Uchiyama Y; Shudo I; Shimamura K; Togashi H; Saito H Am J Ther; 1996 Oct; 3(10):708-14. PubMed ID: 11862226 [TBL] [Abstract][Full Text] [Related]